Farxiga VA Coverage Pathway: How Veterans and Others Can Access Dapagliflozin

What Is Farxiga and Why Does Access Matter?

Farxiga (dapagliflozin) is a sodium-glucose cotransporter-2 (SGLT2) inhibitor approved by the FDA for four distinct indications. Access matters because dapagliflozin is not a lifestyle drug. It is a mortality-reducing, organ-protecting agent backed by large phase III outcomes trials.

The FDA first approved dapagliflozin for type 2 diabetes in January 2014 [1]. Subsequent approvals followed for heart failure with reduced ejection fraction (HFrEF) in May 2020 [2], chronic kidney disease (CKD) in April 2021 [3], and heart failure with mildly reduced or preserved ejection fraction (HFmrEF/HFpEF) in February 2022 [4]. Each approval was supported by a separate outcomes trial, not just surrogate markers.

The Clinical Burden of Paying $620 Out of Pocket

At an average retail price near $620 per month, a patient without insurance or VA coverage faces a $7,440 annual cost for a drug that in DAPA-HF reduced the composite of cardiovascular death, worsening heart failure, or urgent heart failure visit by 26.2% (hazard ratio 0.74; 95% CI 0.65 to 0.85; P<0.001) over a median 18.2 months [5]. Skipping or rationing an SGLT2 inhibitor because of cost is not an abstract inconvenience. For a patient with HFrEF or CKD, it may translate directly into preventable hospitalizations.

The 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure gives dapagliflozin a Class I, Level of Evidence A recommendation for patients with HFrEF, stating: "SGLT2 inhibitors are recommended to reduce HF hospitalizations and cardiovascular mortality." [6] Access programs exist specifically so cost does not become the rate-limiting step.

VA National Formulary Coverage for Dapagliflozin

The VA National Formulary lists dapagliflozin as a covered medication for eligible veterans. Coverage is not automatic for all veterans. The VA applies criteria-based access tied to diagnosis and prior treatment history.

Which Diagnoses Qualify

The VA formulary criteria for dapagliflozin generally align with FDA-approved indications:

• Type 2 diabetes: Dapagliflozin is accessible as add-on therapy when HbA1c remains above target despite metformin or another first-line agent, and when the patient also has established cardiovascular disease, CKD, or high CV risk. The American Diabetes Association 2024 Standards of Care recommend SGLT2 inhibitors for patients with T2D and CKD (eGFR 20 to 45 mL/min/1.73 m²) regardless of HbA1c [7].
• Heart failure (HFrEF and HFpEF/HFmrEF): Veterans with a confirmed diagnosis and ejection fraction documentation can access dapagliflozin under the HF indication. DAPA-HF enrolled 4,744 patients; the number needed to treat to prevent one primary endpoint event was 21 over 18 months [5].
• Chronic kidney disease: DAPA-CKD (N=4,304) showed a 39% reduction in the composite of sustained eGFR decline of 50% or more, end-stage kidney disease, or renal or cardiovascular death (hazard ratio 0.61; 95% CI 0.51 to 0.72; P<0.001) [8]. The VA pharmacy benefit covers dapagliflozin for CKD patients with eGFR between 25 and 75 mL/min/1.73 m², consistent with FDA labeling.

How to Request VA Formulary Access

Veterans obtain dapagliflozin through the VA pharmacy benefit by following these steps:

1. Schedule an appointment with a VA primary care provider or nephrologist or cardiologist, depending on the primary indication.
2. The provider submits a prescription directly into the VA computerized patient record system (CPRS). No prior authorization form is required if the clinical criteria are met and documented.
3. If the prescribing provider is a community-care provider outside the VA network, they must contact the veteran's VA primary care team to coordinate the formulary request. Community-care prescriptions do not automatically route to VA pharmacy.
4. Veterans enrolled in VA health care pay $0 to $11 per 30-day supply depending on service-connected disability rating and copay tier. Service-connected veterans at 50% or higher disability rating typically pay $0 for all medications.

What Happens If VA Denies Coverage

Denials are uncommon when the clinical criteria are met. When a denial does occur, the veteran or provider can request a non-formulary exception through the local VA Pharmacy and Therapeutics (P&T) Committee. Documentation needed includes the primary diagnosis, relevant labs (eGFR, ejection fraction, HbA1c), and a statement of clinical necessity. Appeals that include outcomes-trial citations tend to move faster.

AstraZeneca Manufacturer Savings Programs

AstraZeneca operates two separate programs for patients who need cost assistance with Farxiga: a commercial copay savings card and the AZ&Me Prescription Savings Program for uninsured or underinsured patients.

Farxiga Savings Card (Commercially Insured Patients)

Commercially insured patients who are not enrolled in a federal program (Medicare, Medicaid, TRICARE, or VA) may use the AstraZeneca savings card to pay as little as $0 per month for Farxiga, subject to program eligibility and annual maximum benefit limits. Eligibility requirements include:

• Valid commercial insurance that covers Farxiga (even with a high copay)
• US residency
• Not currently enrolled in any federal or state government-funded insurance program

The savings card is obtained directly at the AstraZeneca patient support website or via the prescribing provider. Pharmacists can apply the card at the point of sale. Income is not a qualifying criterion for the commercial savings card.

AZ&Me Prescription Savings (Uninsured or Underinsured)

The AZ&Me program provides Farxiga at no cost to patients who meet income and insurance eligibility criteria [9]. As of 2026, income thresholds for AZ&Me are approximately 600% of the federal poverty level for most medications, though thresholds shift periodically. Patients apply online or by calling AstraZeneca directly. The process requires:

• Proof of income (pay stubs, tax return, or attestation)
• Proof of residency
• A completed enrollment form signed by the prescribing provider

Approved patients receive a 90-day supply shipped directly or through a participating pharmacy. Processing typically takes 2 to 4 weeks for new applicants. Physicians at HealthRX routinely help patients complete AZ&Me applications as part of the prescription workflow.

Medicare and Medicaid Coverage for Farxiga

Medicare Part D

Medicare Part D plans vary in their formulary placement of dapagliflozin. As of 2025, most benchmark Part D plans include at least one SGLT2 inhibitor on Tier 3 or Tier 4. Patients whose plan does not include Farxiga can request a formulary exception if their provider documents that no covered SGLT2 inhibitor is clinically appropriate or tolerated. The Medicare Extra Help (Low Income Subsidy) program reduces Part D cost-sharing substantially for qualifying patients [10]. Patients with annual income below 150% of the federal poverty level and limited assets may qualify for full Extra Help, reducing generic and brand copays to $0 to $11 per month.

Medicare Part D Coverage Gap

The Inflation Reduction Act of 2022 eliminated the Medicare Part D coverage gap (donut hole) beginning January 1, 2025, capping out-of-pocket drug costs at $2,000 per year for all Part D enrollees [11]. For a Medicare patient paying $200 per month for Farxiga before the cap, this law represents meaningful financial relief.

Medicaid

Medicaid coverage for dapagliflozin varies by state. Most state Medicaid programs cover at least one SGLT2 inhibitor. Patients on Medicaid who are denied Farxiga specifically may be offered empagliflozin or canagliflozin as alternatives, both of which carry comparable cardiovascular outcomes evidence. If dapagliflozin is clinically preferred (for example, in CKD where DAPA-CKD enrollment criteria apply), providers can submit a prior authorization with supporting lab values and trial citations.

TRICARE Coverage for Active Duty and Military Retirees

TRICARE, the military health benefit program for active duty members, National Guard and Reserve members, retirees, and their families, covers dapagliflozin through TRICARE pharmacy benefits. Farxiga is available at military treatment facility (MTF) pharmacies and through the TRICARE Mail Order Pharmacy (TMOP) at the Tier 2 cost-share, which is lower than retail.

Veterans who transitioned from active duty and are now using VA health care should note that TRICARE and VA benefits cannot be used simultaneously for the same service. Patients enrolled in both systems typically elect one or the other as primary for a given medication fill. VA pharmacy is almost always the lower-cost option for service-connected veterans.

Cash-Pay Options and Compounded Dapagliflozin

GoodRx and Discount Programs

For patients without VA, insurance, or program eligibility, GoodRx and similar discount platforms reduce Farxiga's retail price from approximately $620 to $400 to $480 per month at major retail chains. This is still a substantial cost. Mark-Cuban-founded Cost Plus Drugs (costplusdrugs.com) does not carry brand Farxiga as of early 2026, though this may change as the company expands its formulary.

Compounded Dapagliflozin

Compounded dapagliflozin is available through select 503A compounding pharmacies when a licensed prescriber writes for it and a clinical rationale supports its use. Compounded versions can reduce monthly cost to $30 to $80 in many markets. The FDA does not approve compounded drugs, and compounded dapagliflozin is not bioequivalent-tested against brand Farxiga. Patients choosing this route should use a pharmacy that is PCAB-accredited and should maintain regular lab monitoring (eGFR, HbA1c, or BNP depending on indication) to verify therapeutic effect [12].

Telehealth platforms, including HealthRX, can prescribe compounded dapagliflozin for eligible patients who cannot access the brand at a sustainable cost. This pathway is not appropriate for patients with eGFR below 25 mL/min/1.73 m², as both brand and compounded versions carry the same contraindication in advanced CKD [1].

The Clinical Case for Not Skipping Doses

Dapagliflozin is not interchangeable with a generic antihyperglycemic in terms of its organ-protective effects. The FDA approval for CKD is based on DAPA-CKD, where the trial stopped early at interim analysis because the benefit was so clear (P<0.001 by prespecified stopping rules) [8]. The DECLARE-TIMI 58 trial (N=17,160) showed that dapagliflozin reduced the rate of hospitalization for heart failure or cardiovascular death by 17% in patients with T2D and multiple cardiovascular risk factors or established ASCVD (hazard ratio 0.83; 95% CI 0.73 to 0.95; P=0.005) [13].

Renal Dosing and Access Implications

Patients with eGFR between 25 and 45 mL/min/1.73 m² remain eligible for dapagliflozin under the CKD indication despite reduced glycemic efficacy. This matters for access: a VA provider who primarily frames dapagliflozin as a diabetes drug may hesitate to prescribe it when the patient's eGFR drops below the threshold for glucose-lowering benefit. The correct clinical framing is that the renal and cardiac indications extend access to patients who would otherwise be told the drug "isn't working" based on HbA1c.

The FDA label states that dapagliflozin is not recommended when eGFR is persistently below 25 mL/min/1.73 m² for the CKD indication, and not for use in patients with type 1 diabetes due to diabetic ketoacidosis risk [1].

Drug Interactions and Monitoring

Patients on dapagliflozin should hold the drug 3 to 4 days before any major surgery or prolonged NPO period to reduce DKA risk. Volume depletion from concurrent loop diuretics requires dose adjustment monitoring. Baseline and periodic eGFR, blood pressure, and genital hygiene counseling are standard of care. The 2022 ADA Standards reference SGLT2 inhibitors as having a "favorable safety profile when used appropriately" in patients with eGFR as low as 20 mL/min/1.73 m² for the CKD and HF indications [7].

Step-by-Step Access Decision Guide

Use the following sequence to identify the lowest-cost access pathway for a given patient:

1. VA enrollment status: Is the patient enrolled in VA health care? If yes, pursue VA formulary pathway first. VA copay for most veterans is $0 to $11 per 30 days.
2. Active duty / TRICARE: Is the patient active duty or a TRICARE beneficiary? Use MTF pharmacy or TMOP for Tier 2 cost-sharing.
3. Commercial insurance: Does the patient have private insurance? Apply the AstraZeneca savings card. Copay may reach $0/month.
4. Medicare Part D: Is the patient on Medicare? Check formulary tier. Apply for Low Income Subsidy (Extra Help) if income qualifies. The $2,000 annual OOP cap now applies starting January 1, 2025 [11].
5. Uninsured or underinsured: Apply to AZ&Me. Processing takes 2 to 4 weeks. Bridge with GoodRx discount or compounded dapagliflozin through a telehealth prescriber while the application processes.
6. No program eligibility: GoodRx plus compounded dapagliflozin through a PCAB-accredited compounding pharmacy is the lowest-cost remaining option.

How HealthRX Prescribers Handle Dapagliflozin Access

HealthRX clinicians review each patient's payer status, indication, and eGFR at the time of consultation. For VA-eligible patients, the HealthRX provider prepares clinical documentation formatted for VA P&T committee review, including relevant DAPA-HF or DAPA-CKD hazard ratio data. For commercially insured patients, savings card enrollment happens at the point of prescription. For uninsured patients, compounded dapagliflozin or AZ&Me application is initiated in the same visit.

The 2023 Kidney Disease: Improving Global Outcomes (KDIGO) guidelines state: "We recommend treating patients with CKD and type 2 diabetes with an SGLT2 inhibitor if eGFR is >20 mL/min/1.73 m² to reduce the risk of CKD progression and cardiovascular events." [14] Getting that recommendation into a patient's hands is a prescription access problem, not a clinical uncertainty problem.

Patients should verify all program details directly with AstraZeneca and their VA or insurance provider before filling, as program terms change and eligibility criteria are updated periodically. HealthRX reviews this article quarterly to reflect current program status.